AI Article Synopsis
Article Abstract
Objective: To assess the efficacy and safety of an oral formulation of tranexamic acid for the treatment of heavy menstrual bleeding.
Methods: Adult women with heavy menstrual bleeding (mean menstrual blood loss 80 mL or more per cycle) were enrolled in a double-blind, placebo-controlled study. After two pretreatment menstrual cycles, women were randomized to receive tranexamic acid 3.9 g/d or placebo for up to 5 days per menstrual cycle through six cycles. To meet the prespecified three-component primary efficacy end point, mean reduction in menstrual blood loss from baseline with tranexamic acid treatment needed to be 1) significantly greater than placebo, 2) greater than 50 mL, and 3) greater than a predetermined meaningful threshold (36 mL or higher). Health-related quality of life was measured using a validated patient-reported outcome instrument.
Results: Women who received tranexamic acid (n=115) met all three primary efficacy end points: first, a significantly greater reduction in menstrual blood loss of -69.6 mL (40.4%) compared with -12.6 mL (8.2%) in the 72 women who received placebo (P<.001); reduction of menstrual blood loss exceeding a prespecified 50 mL; and last, reduction of menstrual blood loss considered meaningful to women. Compared with women receiving placebo, women treated with tranexamic acid experienced significant improvements in limitations in social or leisure and physical activities, work inside and outside the home, and self-perceived menstrual blood loss (P<.01). The majority of adverse events were mild to moderate in severity, and the incidence of gastrointestinal adverse events was comparable with placebo.
Conclusion: In this study, a new oral tranexamic acid treatment was well tolerated and significantly improved both menstrual blood loss and health-related quality of life in women with heavy menstrual bleeding.
Clinical Trial Registration: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00386308.
Level Of Evidence: I.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/AOG.0b013e3181f20177 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The efficacy of coagulation factor concentrates in the management of patients with trauma-induced coagulopathy: a systematic review and meta-analysis.
Shock
December 2024
Emergency and Critical Care Center, Hokkaido University Hospital, Sapporo, Japan.
Background: Death in the early phase of trauma is primarily attributable to uncontrolled bleeding exacerbated by trauma-induced coagulopathy (TIC). A comprehensive synthesis of the available evidence on interventions for TIC is needed.
Methods: We conducted a systematic review and meta-analysis of blood component products and tranexamic acid administrations for severe trauma patients with TIC.
Post acne erythema (PAE) is a common sequela of acne inflammation, and it refers to telangiectasia and erythematous lesions remaining after the acne treatment. Although some PAE may improve over time, persisting PAE might be esthetically undesirable for patients. The efficacy of various treatment options for PAE has been investigated in many studies but there exists no gold standard treatment modality.
View Article and Find Full Text PDFCell salvage for the management of postpartum haemorrhage.
Cochrane Database Syst Rev
December 2024
Liverpool Reviews and Implementation Group, Department of Health Data Science, University of Liverpool, Liverpool, UK.
Rationale: Postpartum haemorrhage (PPH), defined as a blood loss of 500 mL or more within 24 hours of birth, is the leading global cause of maternal morbidity and mortality. Allogenic blood transfusions are a critical component of PPH management, yet are often unfeasible, particularly in resource-poor settings where maternal morbidity is highest. Autologous cell salvage in the management of PPH has been proposed to combat limitations in access to allogenic blood and potential transfusion-related risks.
View Article and Find Full Text PDFBioactive electrospun polylactic acid/chlorogenic acid-modified chitosan bilayer sponge for acute infection wound healing and rapid coagulation.
Biomater Sci
December 2024
Medical Research center, the Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen 518033, China.
Acute severe trauma is often associated with rapid blood loss and a high risk of infection. Based on these concerns, this study successfully constructed a multifunctional dual-layer bioactive sponge PCCT with rapid hemostatic and infection-preventing ability. Its external surface is an electrospun poly(lactic acid) (PLA) nanofiber thin film layer, which ensures its high air permeability and effectively protects against external bacterial invasion.
View Article and Find Full Text PDFAssociation between IV and topical tranexamic acid use and periprosthetic joint infections in hip and knee arthroplasty: a retrospective study.
BMC Musculoskelet Disord
December 2024
Department of Orthopaedic Surgery, Kaohsiung Chang Gung Memorial Hospital, No. 123, Dapi Road, Niaosong District, Kaohsiung, 833, Taiwan.
Article Synopsis
- Anemia and blood transfusions increase the risk of periprosthetic joint infections (PJI), and tranexamic acid (TXA) is known to reduce surgery-related blood loss and transfusions.
- A retrospective study involving over 8,000 patients examined the effects of TXA on PJI rates following total joint arthroplasty (TJA), comparing those who received TXA (either intravenous or topical) to those who did not.
- Results indicated that TXA significantly reduced PJI occurrences (1.1% vs. 2.1%), decreased blood transfusion rates, and led to shorter hospital stays, with no significant differences in venous thromboembolism or readmission rates.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!